DreamCIS

At a glance

DreamCIS filed 32 disclosures in the last 12 months, including 12 insider and 1 5% holder. The most recent key filing was on Jun 26.

Revenue for 2025 was ₩66.6B, up 13.6% on 2024. Operating margin was 7.9% against 8.6% a year earlier. Debt was 89% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩37.4B and operating profit of ₩2.8B.

The 2025 annual report lists 395 employees with an average tenure of 4 years and average pay of ₩55.1M, #1216 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩112M each on average. It paid no cash dividend for 2025. Hongkong Tigermed Co., Ltd and related parties held 71.70% at year end.

From the 2025 annual report

Staff: 395 (80 men, 315 women), of whom 3 on fixed-term contracts. Total pay for the year: ₩21.8B. Directors and auditors: 7, paid ₩784.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

Hongkong Tigermed Co., Ltd holds 59.34%; with 3 related parties the group holds 71.70% of common shares at year end.

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary